healthcare research worldwide limitedEstimated Valuation
£8.4m
Pomanda estimates the enterprise value of HEALTHCARE RESEARCH WORLDWIDE LIMITED at £8.4m based on a Turnover of £14.5m and 0.58x industry multiple (adjusted for size and gross margin).
healthcare research worldwide limitedEstimated Valuation
£1.7m
Pomanda estimates the enterprise value of HEALTHCARE RESEARCH WORLDWIDE LIMITED at £1.7m based on an EBITDA of £501.2k and a 3.39x industry multiple (adjusted for size and gross margin).
healthcare research worldwide limitedEstimated Valuation
£13.6m
Pomanda estimates the enterprise value of HEALTHCARE RESEARCH WORLDWIDE LIMITED at £13.6m based on Net Assets of £8.3m and 1.64x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Healthcare Research Worldwide LimitedOverview
Healthcare Research Worldwide Limited is a live company located in wallingford, OX10 0DB with a Companies House number of 04240899. It operates in the market research and public opinion polling sector, SIC Code 73200. Founded in June 2001, it's largest shareholder is
mathematical market research ltd
with a 100% stake. Healthcare Research Worldwide Limited is a mature,
mid sized company, Pomanda has estimated its turnover at
£14.5m with
healthy
growth in recent years.
Healthcare Research Worldwide Limited Health Check
Pomanda's financial health check has awarded Healthcare Research Worldwide Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 4 areas for improvement. Company Health Check FAQs
Health Rating3.5out of 5
3 Strong
4 Regular
4 Weak
Size
annual sales of £14.5m, make it larger than the average company (£9.6m)
£14.5m - Healthcare Research Worldwide Limited
£9.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 10%, show it is growing at a similar rate (9.2%)
10% - Healthcare Research Worldwide Limited
9.2% - Industry AVG
Production
with a gross margin of 57.4%, this company has a comparable cost of product (66.7%)
57.4% - Healthcare Research Worldwide Limited
66.7% - Industry AVG
Profitability
an operating margin of 3.2% make it less profitable than the average company (5.5%)
3.2% - Healthcare Research Worldwide Limited
5.5% - Industry AVG
Employees
with 65 employees, this is similar to the industry average (60)
65 - Healthcare Research Worldwide Limited
60 - Industry AVG
Pay Structure
on an average salary of £91.2k, the company has a higher pay structure (£69.5k)
£91.2k - Healthcare Research Worldwide Limited
£69.5k - Industry AVG
Efficiency
resulting in sales per employee of £223.1k, this is more efficient (£149.5k)
£223.1k - Healthcare Research Worldwide Limited
£149.5k - Industry AVG
Debtor Days
it gets paid by customers after 384 days, this is later than average (65 days)
384 days - Healthcare Research Worldwide Limited
65 days - Industry AVG
Creditor Days
its suppliers are paid after 58 days, this is slower than average (39 days)
58 days - Healthcare Research Worldwide Limited
39 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Healthcare Research Worldwide Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 0 weeks, this is less cash available to meet short term requirements (15 weeks)
0 weeks - Healthcare Research Worldwide Limited
15 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 57.4%, this is a similar level of debt than the average (58.9%)
57.4% - Healthcare Research Worldwide Limited
58.9% - Industry AVG
HEALTHCARE RESEARCH WORLDWIDE LIMITED financials
EXPORT
Healthcare Research Worldwide Limited's latest turnover from March 2024 is £14.5 million and the company has net assets of £8.3 million. According to their latest financial statements, Healthcare Research Worldwide Limited has 65 employees and maintains cash reserves of £1.1 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Turnover
14,498,997
14,951,990
15,653,130
11,024,464
19,343,328
16,202,465
10,049,372
8,332,212
5,418,225
6,912,178
15,210,598
21,636,086
7,077,618
14,087,449
11,221,443
Other Income Or Grants
Cost Of Sales
6,180,621
6,922,991
7,734,328
5,261,897
7,923,796
6,341,103
4,122,166
3,431,092
2,202,440
2,890,084
6,488,143
9,430,245
2,829,275
5,888,330
4,813,264
Gross Profit
8,318,376
8,028,999
7,918,802
5,762,567
11,419,532
9,861,362
5,927,207
4,901,120
3,215,785
4,022,094
8,722,455
12,205,840
4,248,343
8,199,119
6,408,179
Admin Expenses
7,859,515
6,892,758
5,392,451
4,443,291
11,355,839
9,182,500
5,338,259
3,948,015
3,058,798
3,380,490
8,221,130
11,906,259
3,915,753
7,975,507
6,025,460
Operating Profit
458,861
1,136,241
2,526,351
1,319,276
63,693
678,862
588,948
953,105
156,987
641,604
501,325
299,581
332,590
223,612
382,719
Interest Payable
957
8
44
45
387
386
Interest Receivable
1
8
5
6
10
1
1
Pre-Tax Profit
457,904
1,136,241
2,254,533
1,203,960
63,686
678,869
588,953
953,111
156,998
641,605
501,326
299,537
332,545
223,225
382,333
Tax
-49,521
-98,128
-208,183
-135,352
-12,100
-128,985
-111,901
-190,622
-31,399
-134,737
-115,305
-71,889
-86,462
-62,503
-107,053
Profit After Tax
408,383
1,038,113
2,046,350
1,068,608
51,586
549,884
477,052
762,489
125,598
506,868
386,021
227,648
246,083
160,722
275,280
Dividends Paid
Retained Profit
408,383
1,038,113
2,046,350
1,068,608
51,586
549,884
477,052
762,489
125,598
506,868
386,021
227,648
246,083
160,722
275,280
Employee Costs
5,925,341
5,425,976
4,436,181
3,788,927
2,231,939
2,221,736
2,281,949
1,974,824
1,917,120
3,011,314
6,287,590
10,285,746
3,015,804
5,343,978
4,011,488
Number Of Employees
65
57
49
41
39
40
43
37
38
59
123
206
64
112
85
EBITDA*
501,211
1,160,673
2,542,718
1,327,234
75,296
690,828
596,492
961,458
168,010
654,372
511,184
310,861
342,199
232,209
386,221
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Tangible Assets
91,718
94,762
39,478
22,748
18,485
25,209
31,637
7,447
8,708
19,732
18,135
17,237
15,449
18,867
15,797
Intangible Assets
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
91,718
94,762
39,478
22,748
18,485
25,209
31,637
7,447
8,708
19,732
18,135
17,237
15,449
18,867
15,797
Stock & work in progress
Trade Debtors
15,260,402
12,737,708
10,471,654
8,091,515
5,938,989
5,146,869
2,705,005
2,403,025
1,296,998
1,517,876
3,080,125
3,923,957
1,415,243
2,618,317
2,051,270
Group Debtors
3,989,470
6,878,742
9,684,109
6,951,547
5,550,023
3,621,108
4,611,515
4,480,020
4,209,721
2,901,573
Misc Debtors
218,787
88,384
16,053
21,533
10,611
14,284
42,120
1,083
4,126
17,096
Cash
1,090
1,090
1,000
1,000
1,000
1,000
1,000
1,000
3,950
148
310
misc current assets
total current assets
19,469,749
19,705,924
20,172,816
15,065,595
11,500,623
8,783,261
7,359,640
6,885,128
5,514,795
4,436,693
3,080,435
3,923,957
1,415,243
2,618,317
2,051,270
total assets
19,561,467
19,800,686
20,212,294
15,088,343
11,519,108
8,808,470
7,391,277
6,892,575
5,523,503
4,456,425
3,098,570
3,941,194
1,430,692
2,637,184
2,067,067
Bank overdraft
252
1,357
36
11,869
Bank loan
Trade Creditors
991,659
1,377,370
1,691,959
1,166,986
864,874
1,116,102
1,208,526
618,589
827,402
447,187
1,802,815
3,031,460
747,249
2,201,145
1,779,917
Group/Directors Accounts
10,043,850
8,493,965
8,798,945
6,365,875
5,140,278
2,330,615
1,356,825
1,444,259
862,419
802,934
other short term finances
hp & lease commitments
other current liabilities
172,112
1,983,888
2,827,977
2,714,153
1,740,983
1,640,618
1,653,240
2,138,928
1,905,461
1,403,681
total current liabilities
11,207,621
11,855,223
13,318,881
10,247,014
7,746,387
5,087,335
4,218,591
4,201,776
3,595,282
2,653,802
1,802,815
3,031,460
748,606
2,201,181
1,791,786
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
23,160
23,160
9,223
3,489
3,489
3,489
4,924
89
total long term liabilities
23,160
23,160
9,223
3,489
3,489
3,489
4,924
89
total liabilities
11,230,781
11,878,383
13,328,104
10,250,503
7,749,876
5,090,824
4,223,515
4,201,865
3,595,282
2,653,802
1,802,815
3,031,460
748,606
2,201,181
1,791,786
net assets
8,330,686
7,922,303
6,884,190
4,837,840
3,769,232
3,717,646
3,167,762
2,690,710
1,928,221
1,802,623
1,295,755
909,734
682,086
436,003
275,281
total shareholders funds
8,330,686
7,922,303
6,884,190
4,837,840
3,769,232
3,717,646
3,167,762
2,690,710
1,928,221
1,802,623
1,295,755
909,734
682,086
436,003
275,281
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2020
Mar 2019
Mar 2018
Mar 2017
Mar 2016
Mar 2015
Mar 2014
Mar 2013
Mar 2012
Mar 2011
Mar 2010
Operating Activities
Operating Profit
458,861
1,136,241
2,526,351
1,319,276
63,693
678,862
588,948
953,105
156,987
641,604
501,325
299,581
332,590
223,612
382,719
Depreciation
42,350
24,432
16,367
7,958
11,603
11,966
7,544
8,353
11,023
12,768
9,859
11,280
9,609
8,597
3,502
Amortisation
Tax
-49,521
-98,128
-208,183
-135,352
-12,100
-128,985
-111,901
-190,622
-31,399
-134,737
-115,305
-71,889
-86,462
-62,503
-107,053
Stock
Debtors
-236,175
-466,982
5,107,221
3,564,972
2,717,362
1,423,621
474,512
1,373,283
1,074,300
1,356,420
-843,832
2,508,714
-1,203,074
567,047
2,051,270
Creditors
-385,711
-314,589
524,973
302,112
-251,228
-92,424
589,937
-208,813
380,215
-1,355,628
-1,228,645
2,284,211
-1,453,896
421,228
1,779,917
Accruals and Deferred Income
-1,811,776
-844,089
113,824
973,170
100,365
-12,622
-485,688
233,467
501,780
1,403,681
Deferred Taxes & Provisions
13,937
5,734
-1,435
4,835
89
Cash flow from operations
-1,509,622
384,786
-2,128,155
-1,097,808
-2,805,029
-968,259
119,163
-577,704
-55,694
-788,732
11,066
14,469
4,915
23,887
7,815
Investing Activities
capital expenditure
-39,306
-79,716
-33,097
-12,221
-4,879
-5,538
-31,734
-7,092
1
-14,365
-10,757
-13,068
-6,191
-11,667
-19,299
Change in Investments
cash flow from investments
-39,306
-79,716
-33,097
-12,221
-4,879
-5,538
-31,734
-7,092
1
-14,365
-10,757
-13,068
-6,191
-11,667
-19,299
Financing Activities
Bank loans
Group/Directors Accounts
1,549,885
-304,980
2,433,070
1,225,597
2,809,663
973,790
-87,434
581,840
59,485
802,934
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
1
interest
-957
-7
8
5
6
10
1
1
-44
-45
-387
-386
cash flow from financing
1,548,928
-304,980
2,433,070
1,225,597
2,809,656
973,798
-87,429
581,846
59,495
802,935
1
-44
-45
-387
-385
cash and cash equivalents
cash
90
-2,950
3,802
-162
310
overdraft
-252
252
-1,357
1,321
-11,833
11,869
change in cash
90
252
-252
-2,950
3,802
-162
310
1,357
-1,321
11,833
-11,869
healthcare research worldwide limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for healthcare research worldwide limited. Get real-time insights into healthcare research worldwide limited's credit score, group structure and payment trends.
Healthcare Research Worldwide Limited Competitor Analysis
Perform a competitor analysis for healthcare research worldwide limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mid companies, companies in OX10 area or any other competitors across 12 key performance metrics.
healthcare research worldwide limited Ownership
HEALTHCARE RESEARCH WORLDWIDE LIMITED group structure
Healthcare Research Worldwide Limited has no subsidiary companies.
HEALTHCARE RESEARCH WORLDWIDE LIMITED Shareholders
The sole shareholder of Healthcare Research Worldwide Limited is Mathematical Market Research Ltd.
mathematical market research ltd
100%
healthcare research worldwide limited directors
Healthcare Research Worldwide Limited currently has 5 directors.
The longest serving directors include
Prof David Thomson (Jun 2001) and
Ms Jeanette Kaye (Jul 2007).
wallingford house, 46 high street, wallingford, oxfordshire, OX10 0DB
Bank
HSBC BANK PLC
Legal Advisor
-
healthcare research worldwide limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 5 charges/mortgages relating to healthcare research worldwide limited. Currently there are 2 open charges and 3 have been satisfied in the past.
healthcare research worldwide limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for HEALTHCARE RESEARCH WORLDWIDE LIMITED. This can take several minutes, an email will notify you when this has completed.
healthcare research worldwide limitedCompanies House Filings - See Documents
